Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

Blood (2025) 146 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2025-2237

Published: 2025

Journal Articles

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).

Sikander Ailawadhi, Divaya Bhutani, Antje Hoering, Adam Rosenthal, J Christine Ye, Prashant Kapoor, Saad Usmani, Manisha Bhutani, S. Vincent Rajkumar, Paul Gater, Robert Orlowski

Blood (2025) 146 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2025-1840

Published: 2025

Journal Articles

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Blood (2025) 146 (Supplement 1): 692.

https://doi.org/10.1182/blood-2025-692

Published: 2025

Journal Articles

Charlotte African American MGUS project (CHAAMP): A prospective pilot study of MGUS screening in black and/or African American adults

Manisha Bhutani, Myra Robinson, Margarita Dzhanumova, Samantha Bradley, Adrienne Dobbins, Robin Cox, David Foureau, Shebli Atrash, Barry Paul, Cindy Varga, Christopher Ferreri, Reed Friend, Mauricio Pineda-Roman, Brittany Neelands, Joseph Mikhael, Nadine Barrett, Peter Voorhees

Blood (2025) 146 (Supplement 1): 8244.

https://doi.org/10.1182/blood-2025-8244

Published: 2025

Journal Articles

T-cell redirecting therapies in multiple myeloma: Barriers and knowledge gap among patients, community physicians, and caregivers

Abena Prempeh, Myra Robinson, Zalak Shah, Ami Ndiaye, Nicole Serapin, Barry Paul, Cindy Varga, Reed Friend, Christopher Ferreri, Shebli Atrash, John Mckay, Peter Voorhees, Manisha Bhutani

Blood (2025) 146 (Supplement 1): 6347.

https://doi.org/10.1182/blood-2025-6347

Published: 2025

Journal Articles

Defining functional high-risk multiple myeloma in the era of modern induction therapy

Blood (2025) 146 (Supplement 1): 4014.

https://doi.org/10.1182/blood-2025-4014

Published: 2025

Journal Articles

Tradeoff between vaccine-induced immunity and depth of response following autologous stem cell transplantation in multiple myeloma

David Foureau, Dragos Plesca, Fei Guo, Barry Paul, Christopher Ferreri, Shebli Atrash, Cindy Varga, Reed Friend, Ami Ndiaye, Lawrence Druhan, Allison Karabinos, Jessica McElwee, Grace Elsey, Allison Morse, Meagan Reinfried, Alexandra Wolff, Peter Voorhees, Manisha Bhutani

Blood (2025) 146 (Supplement 1): 4005.

https://doi.org/10.1182/blood-2025-4005

Published: 2025

Journal Articles

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Blood (2025) 146 (17): 2063–2072.

https://doi.org/10.1182/blood.2025029773

Published: 2025

Includes: Supplemental data

Journal Articles

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Blood blood.2025029360.

https://doi.org/10.1182/blood.2025029360

Published: 2025

Includes: Supplemental data

Journal Articles

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Blood (2024) 144 (Supplement 1): 594.

https://doi.org/10.1182/blood-2024-200300

Published: 2024

Journal Articles

Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center

Semegne Hiruy, Myra Robinson, Shebli Atrash, Barry Paul, Reed Friend, Cindy Varga, Christopher J Ferreri, Mauricio Pineda-Roman, Peter M. Voorhees, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 3769.

https://doi.org/10.1182/blood-2024-202137

Published: 2024

Journal Articles

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Abdullah Mohammad Khan, Al-Ola Abdallah, Nausheen Ahmed, Shebli Atrash, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2024-208692

Published: 2024

Journal Articles

A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

Morie A. Gertz, Heather J. Landau, Vaishali Sanchorawala, Manisha Bhutani, Jeffrey A. Zonder, Michael Rosenzweig, Gray Magee, Cynthia Campos, Irina Yermilov, Eunice Chang, Michael S. Broder, Preeti Bajaj

Blood (2024) 144 (Supplement 1): 3665.

https://doi.org/10.1182/blood-2024-206132

Published: 2024

Journal Articles

Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel

Barry Paul, Myra Robinson, James Symanowski, David M Foureau, Sarah Norek, Manisha Bhutani, Christopher Ferreri, Ami P Ndiaye, Jordan Robinson, Shebli Atrash, Cindy Varga, Reed Friend, Mauricio Pineda-Roman, April Smith, Jessica Duda, Lance Cooper, Amani Kitali, Peter M. Voorhees

Blood (2024) 144 (Supplement 1): 7027.

https://doi.org/10.1182/blood-2024-208830

Published: 2024

Journal Articles

The Scope of Academic and Industry Sponsorship in Shaping the Future of AL Amyloidosis Research

Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Forat Lutfi, Joseph P. McGuirk, Al-Ola Abdallah, Faiz Anwer, Manisha Bhutani, Shebli Atrash

Blood (2024) 144 (Supplement 1): 7595.

https://doi.org/10.1182/blood-2024-205422

Published: 2024

Journal Articles

Supportive Care Utilization in Patients with Multiple Myeloma-a Single Center Retrospective Study

Darryl Chang, Myra Robinson, Rupali Bose, Hamid Ehsan, Arunkumar Krishnan, Shanice Borden, Peter M. Voorhees, Barry Paul, Manisha Bhutani, Cindy Varga, Christopher Ferreri, Shebli Atrash

Blood (2024) 144 (Supplement 1): 2287.

https://doi.org/10.1182/blood-2024-209358

Published: 2024

Journal Articles

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Blood (2024) 144 (Supplement 1): 3792.5.

https://doi.org/10.1182/blood-2024-210957

Published: 2024

Journal Articles

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Cindy Varga, Myra Robinson, Vikas Gupta, Craig C. Hofmeister, Ajay K. Nooka, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Shanice Borden, Christopher Ferreri, Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Nisha S. Joseph

Blood (2024) 144 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2024-204388

Published: 2024

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2024-200958

Published: 2024

Journal Articles

Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution

Cindy Varga, Ferdous Ahmed, Marvin Knight, Manisha Bhutani, Barry Paul, Shebli Atrash, Peter M. Voorhees, Christopher Ferreri

Blood (2024) 144 (Supplement 1): 4720.

https://doi.org/10.1182/blood-2024-204361

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Charlotte African American MGUS project (CHAAMP): A prospective pilot study of MGUS screening in black and/or African American adults

T-cell redirecting therapies in multiple myeloma: Barriers and knowledge gap among patients, community physicians, and caregivers

Defining functional high-risk multiple myeloma in the era of modern induction therapy

Tradeoff between vaccine-induced immunity and depth of response following autologous stem cell transplantation in multiple myeloma

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel

The Scope of Academic and Industry Sponsorship in Shaping the Future of AL Amyloidosis Research

Supportive Care Utilization in Patients with Multiple Myeloma-a Single Center Retrospective Study

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only